Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Murray And Poole Enterprises Ltd. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This indicates a focused prosecution strategy, likely centered on a specific pharmaceutical or biological invention. The limited volume of active matters suggests that the company is prioritizing the protection of a core asset in its current patent filings.
The company's active prosecution is limited to a distinct examiner and 1 distinct art unit. This concentration suggests that the subject matter is being evaluated by a specialized technical group at the patent office. JARED BARSKY is the busiest examiner for the portfolio, currently handling the busiest examiner pending office action. This examiner is the only one currently reviewing the company's patent applications, which allows for a more consistent and focused technical dialogue.
With only 1 pending office action, the administrative burden on the company is minimal. The prosecution team can focus entirely on the specific requirements of the distinct art unit involved. The outcome of the current interaction with JARED BARSKY will be the primary factor in the company's immediate success within the Biotechnology & Pharmaceuticals sector, requiring a response that is highly tailored to this examiner's specific technical standards.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 1 | 50.2% | +22.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17385734 | COLCHICINE SALICYLATE DERIVATIVES AND METHODS OF TREATMENT | BARSKY, JARED | 28d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17385734 | COLCHICINE SALICYLATE DERIVATIVES AND METHODS OF TREATMENT | BARSKY, JARED | 1628 | §103 | Final Rejection | 28d overdue | Pending | Jul 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMurray And Poole Enterprises Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Jared Barsky has the most, with 1 of Murray And Poole Enterprises Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.